Zhao Yueshui, Deng Jian, Rao Shuangfeng, Guo Sipeng, Shen Jing, Du Fukuan, Wu Xu, Chen Yu, Li Mingxing, Chen Meijuan, Li Xiaobing, Li Wanping, Gu Li, Sun Yuhong, Zhang Zhuo, Wen Qinglian, Xiao Zhangang, Li Jing
Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Cancers (Basel). 2022 Aug 27;14(17):4160. doi: 10.3390/cancers14174160.
Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient's own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
在过去十年中，免疫疗法，尤其是基于细胞的免疫疗法，为癌症治疗提供了新策略。近期临床研究表明，对晚期实体瘤采用肿瘤浸润淋巴细胞（TILs）的细胞转移显示出良好疗效。TIL疗法是一种基于细胞的免疫疗法，利用来自实体瘤微环境的患者自身免疫细胞来杀死肿瘤细胞。在本综述中，我们全面总结了TIL分离与生成的当前策略及挑战。此外，总结并讨论了TIL疗法的当前临床经验，重点在于淋巴细胞清除方案、白细胞介素-2的使用及相关毒性。此外，我们强调了TIL疗法单独使用以及与其他类型疗法联合用于实体癌治疗的临床试验。最后，还讨论了TIL疗法用于实体瘤治疗的局限性、未来潜力及方向。
